FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.
Minnesota Daily8d
Insulin costs capped at $35 per month in Minnesota
Minnesota Attorney General Keith Ellison and pharmaceutical company Novo Nordisk reached a settlement to cap insulin costs at ...
pharmaphorum2d
Civica plans shake-up of insulin sector with low-cost biosimilars
The average wholesale prices of the originator insulin are around $329 per vial and $510 for five pens, according to Civica, which says it will start clinical trials of the biosimilars this year ...
Press-Telegram15dOpinion
Insulin prices are falling due to market forces — no price caps required
If California patients pay more than $35 per month for insulin now, it’s in large part because PBMs have rigged the system in ...
Santa Clarita Radio15d
Access To Affordable Insulin Amid Rising Costs
As insulin prices in the United States continue to rise, making it increasingly difficult for diabetic patients to afford essential medication, Insulin Outlet is stepping in to offer a cost-effective ...
Medscape21h
FDA Okays New Rapid-Acting Biosimilar Insulin for Diabetes
The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...
BioSpace1d
Sanofi Challenges Novo With First FDA Nod for NovoLog Biosimilar
Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for ...
MedPage Today4d
FDA OKs First Rapid-Acting Insulin Biosimilar for Diabetes
The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...
Monthly Prescribing Reference9h
FDA Approves Merilog, a Rapid-Acting Insulin Biosimilar Product
Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.